Page last updated: 2024-10-27

fluoxetine and Hearing Loss, Sensorineural

fluoxetine has been researched along with Hearing Loss, Sensorineural in 1 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Hearing Loss, Sensorineural: Hearing loss resulting from damage to the COCHLEA and the sensorineural elements which lie internally beyond the oval and round windows. These elements include the AUDITORY NERVE and its connections in the BRAINSTEM.

Research Excerpts

ExcerptRelevanceReference
"We report 2 patients with autism and mental retardation who developed catatonic symptoms at the onset of puberty."1.36Onset of catatonia at puberty: electroconvulsive therapy response in two autistic adolescents. ( Barbosa, V; Ghaziuddin, M; Ghaziuddin, N; Gih, D; Maixner, DF, 2010)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ghaziuddin, N1
Gih, D1
Barbosa, V1
Maixner, DF1
Ghaziuddin, M1

Other Studies

1 other study available for fluoxetine and Hearing Loss, Sensorineural

ArticleYear
Onset of catatonia at puberty: electroconvulsive therapy response in two autistic adolescents.
    The journal of ECT, 2010, Volume: 26, Issue:4

    Topics: Adolescent; Age of Onset; Aggression; Antidepressive Agents, Second-Generation; Antipsychotic Agents

2010